Literature DB >> 10715354

[123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder.

M Willeit1, N Praschak-Rieder, A Neumeister, W Pirker, S Asenbaum, O Vitouch, J Tauscher, E Hilger, J Stastny, T Brücke, S Kasper.   

Abstract

BACKGROUND: Numerous findings indicate alterations in brain serotonin systems in seasonal affective disorder (SAD). [(123)I]-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([(123)I]-beta-CIT) labels serotonin transporters (5-HTTs) in the midbrain. We performed a [(123)I]-beta-CIT single photon emission computer tomography (SPECT) study under the hypothesis of lower [(123)I]-beta-CIT binding reflecting reduced central 5-HTT availability in depressed SAD patients.
METHODS: Depressed SAD patients and healthy control subjects were investigated using [(123)I]-beta-CIT SPECT 4 hours and again 24 hours after tracer injection. Subjects had either never used psychotropic medication or had been drug-free for at least 6 months prior to the investigation. Specific-to-nondisplaceable partition coefficient (V(3)") was calculated for the thalamus-hypothalamus and the midbrain-pons; the cerebellum served as a reference region.
RESULTS: Patients showed a reduction in V(3)" in thalamus-hypothalamus (2.41+/-0.3 vs. 2.84+/-0.4; p = .026) 24 hours post tracer injection (p.i.). No difference between patients and control subjects was found in midbrain-pons (1.31+/-0.2 vs. 1.42+/-0.2; p = .39). No differences were detected in the SPECT acquisitions 4 hours p.i.
CONCLUSIONS: Depressed SAD patients showed lower specific-to-nondisplaceable [(123)I]-beta-CIT binding in the region of interest (ROI) thalamus-hypothalamus. The small size of the midbrain-pons ROI may have contributed to the failure to show a difference in this ROI as well. Similar to reduced midbrain 5-HTT availability in nonseasonal depression, depression in SAD seems to be associated with reduced 5-HTT availability to the thalamus-hypothalamus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715354     DOI: 10.1016/s0006-3223(99)00293-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  27 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

Review 2.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 3.  Tracking the estrogen receptor in neurons: implications for estrogen-induced synapse formation.

Authors:  B McEwen; K Akama; S Alves; W G Brake; K Bulloch; S Lee; C Li; G Yuen; T A Milner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

5.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Authors:  Matthew S Milak; Ramin V Parsey; Leilani Lee; Maria A Oquendo; Doreen M Olvet; Francoise Eipper; Kevin Malone; J John Mann
Journal:  Psychiatry Res       Date:  2009-05-14       Impact factor: 3.222

6.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

7.  123I-ADAM SPECT imaging of serotonin transporter binding in patients with night eating syndrome: a preliminary report.

Authors:  Jennifer D Lundgren; Andrew B Newberg; Kelly C Allison; Nancy A Wintering; Karl Ploessl; Albert J Stunkard
Journal:  Psychiatry Res       Date:  2008-02-20       Impact factor: 3.222

8.  A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder.

Authors:  Adam Moscovitch; Carl A Blashko; John M Eagles; Guy Darcourt; Christopher Thompson; Siegfried Kasper; Roger M Lane
Journal:  Psychopharmacology (Berl)       Date:  2003-09-19       Impact factor: 4.530

9.  Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

Authors:  Maartje M L de Win; Liesbeth Reneman; Johannes B Reitsma; Gerard J den Heeten; Jan Booij; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

Review 10.  Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.

Authors:  Deepika Suri; Cátia M Teixeira; Martha K Caffrey Cagliostro; Darshini Mahadevia; Mark S Ansorge
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.